| Identification | Back Directory | [Name]
2,6-Piperidinedione, 3-[4-[4-[4-[1-[4-[[5-chloro-4-[[2-(dimethylphosphinyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-4-piperidinyl]-1-piperazinyl]-1-butyn-1-yl]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]- | [CAS]
2570251-68-0 | [Synonyms]
HJM-561
3-(4-(4-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)but-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
2,6-Piperidinedione, 3-[4-[4-[4-[1-[4-[[5-chloro-4-[[2-(dimethylphosphinyl)phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-4-piperidinyl]-1-piperazinyl]-1-butyn-1-yl]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]- | [Molecular Formula]
C45H51ClN9O5P | [MOL File]
2570251-68-0.mol | [Molecular Weight]
864.37 |
| Hazard Information | Back Directory | [Uses]
HJM-561 is a potent, selective, orally bioavailable EGFR PROTAC. HJM-561 overcomes osimertinib (HY-15772)-resistant EGFR triple mutations and has anti-tumor activity[1]. | [References]
[1] Du Y, et al. HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations. Mol Cancer Ther. 2022 Jul 5;21(7):1060-1066. DOI:10.1158/1535-7163.MCT-21-0835 |
|
|